Arax Advisory Partners’s Sana Biotechnology SANA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$144K Sell
49,475
-10,083
-17% -$35.1K ﹤0.01% 2558
2026
Q2
$208K Buy
59,558
+37,444
+169% +$121K ﹤0.01% 2227
2026
Q1
$63.7K Sell
22,114
-36,914
-63% -$145K ﹤0.01% 1584
2025
Q4
$240K Sell
59,028
-105,903
-64% -$474K 0.01% 951
2025
Q3
$586K Buy
+164,931
New +$596K 0.01% 846
2024
Q4
– Sell
-150
Closed -$624 – 2701
2024
Q3
$624 Hold
150
– – ﹤0.01% 2370
2024
Q2
$819 Buy
+150
New +$1.2K ﹤0.01% 2230

Other funds holding SANA

Arax Advisory Partners's SANA Position: Q3 2026 in Review

Arax Advisory Partners reduced its Sana Biotechnology (SANA) stake by 17% in Q3 2026, selling an estimated $35.1K and leaving 49,475 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #2558.

Arax Advisory Partners first reported a position in SANA in Q2 2024 and has held it in 7 quarters since. The position peaked at $586K in Q3 2025. 203 funds tracked by Wall St. Rank hold SANA as of Q3 2026.

  • Arax Advisory Partners held 49,475 shares of Sana Biotechnology worth $144K as of Q3 2026.
  • Arax Advisory Partners sold 10,083 Sana Biotechnology shares in Q3 2026, an estimated $35.1K.
  • Sana Biotechnology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q3 2026, its #2558 holding.
  • Arax Advisory Partners first reported a position in Sana Biotechnology in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Sana Biotechnology position peaked at $586K in Q3 2025.
  • 203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2026.

Based on Arax Advisory Partners's 13F filing for Q3 2026, filed 12 Nov 2026.